BioAffinity Technologies (BIAF) announced that the Japan Patent Office has issued a certificate of grant of patent to BioAffinity Technologies for the method of predicting the likelihood of lung cancer used by the CyPath Lung diagnostic test for early-stage lung cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- BioAffinity Technologies announces closing of $2.6M registered direct offering
- BioAffinity Technologies announces pricing of $2.66M registered direct offering
- BioAffinity Technologies’ CyPath lung cancer test supported in publication
- bioAffinity Technologies Welcomes Back CFO for Future Growth
- BioAffinity Technologies names J. Michael Edwards CFO
Questions or Comments about the article? Write to editor@tipranks.com